Summary & Overview
HCPCS C9038: Injection, mogamulizumab-kpkc, 1 mg
HCPCS Level II code C9038 denotes injection of mogamulizumab-kpkc measured per 1 mg. As a code for a targeted monoclonal antibody therapy, it is relevant to oncology and specialty infusion billing and impacts national drug utilization and specialty pharmacy workflows. Payers and providers use this HCPCS Level II code to report doses provided in outpatient infusion centers and oncology clinics.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how C9038 is applied in billing for biologic injections, summarizes national benchmarking considerations for payers, and reviews relevant clinical context for infusion-based monoclonal antibody administration. Readers will find benchmarks for coverage and reimbursement practices, an overview of policy updates affecting HCPCS reporting for specialty injectables, and practical notes on service-line implications for oncology and infusion centers.
The report is intended for revenue cycle leaders, specialty pharmacy managers, and policy analysts seeking concise guidance on coding implications, payer coverage patterns, and operational impacts related to billing mogamulizumab-kpkc using HCPCS Level II code C9038.
Billing Code Overview
HCPCS Level II code C9038 describes Injection, mogamulizumab-kpkc, 1 mg. This code represents a billed unit for the administration of the monoclonal antibody mogamulizumab-kpkc, with the service type reflecting drug administration/injectable biologic. The typical site of service for this drug is an outpatient infusion or oncology clinic where intravenous or subcutaneous biologic therapies are prepared and administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with relapsed mycosis fungoides (cutaneous T-cell lymphoma) presents to an outpatient oncology infusion center for administration of mogamulizumab-kpkc. The patient has documented progressive skin plaques unresponsive to prior systemic therapies and meets clinical criteria for target-directed monoclonal antibody therapy. The typical workflow includes: pre-visit nursing triage and review of recent labs (CBC, CMP), verification of informed consent and indication, review of prior infusion reactions, and confirmation of venous access. On arrival, vital signs are taken and an intravenous line is placed. The oncology nurse prepares the weight-based dose authorized by the provider, calculates total milligrams, and prepares the infusion per institutional policy. The clinician verifies the order and documents the indication and planned infusion parameters. Mogamulizumab-kpkc is administered intravenously under direct nursing supervision, with monitoring for infusion-related reactions and dermatologic adverse events. Post-infusion observation is performed per protocol, documentation of tolerated dose or any adverse events is recorded, and an outpatient follow-up visit is scheduled to assess response and toxicity. Billing captures the drug administration using the HCPCS Level II billing code C9038 for mogamulizumab-kpkc, reported per milligram as indicated by the product description.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |